The Bivalent Booster Protects Against New COVID-19 Variants, New Data Show
6 days ago - By Time
The Omicron variant has morphed into more than half a dozen different strains-the latest of which include BQ.1.1 and XBB.1, and XBB.1.5. Combined, these variants and their close relatives now account for nearly 90% of new COVID-19 infections in the U.S.
But so far, no COVID-19 vaccine directly targets them. Instead, the latest bivalent formulation of the booster was designed against the Omicron variants BA.4 and BA.5, which are no longer widely circulating.
So how well does it protect against the newer ones?
The first look at a vaccine's effectiveness generally comes from lab-based data...
Read more ...
The headlines of Care Mag
Drink Your Coffee First Thing? Add This To Make It Blood Sugar Friendly
This one addition can make all the difference
STAT+: KKR veteran sets records with $3.9 billion health care fund
The former head of health care investing at private equity giant KKR has set records with the first fundraising for his new firm. The firm, Patient Square Capital, closed on...
How To Ground Yourself When You Feel Uncomfortable In Your Body
A healthy relationship with your body begins by being comfortable with your physicality.
Curing Fish Is Easier Than You Think: An RD's Go-To Recipe
This omega-3-packed only requires a few minutes of prep work.
A Peek Inside An M.D.'s "Biohacker Room" + Her Favorite Tools For Sleep
At the end of the day, you can find Molly Maloof, M.D. on an infrared mat.
Oh, Cool: Tiktok “Invented” Another Very Normal Skin Care Habit
It's actually top notch for thirsty skin.
New Research Reveals The Top 3 Ways To Wake Up Energized Every Morning
Being a "morning person" isn't genetic, after all.
Opinion: Promises - and pitfalls - of ChatGPT-assisted medicine
Not long after the artificial intelligence company OpenAI released its ChatGPT chatbot, the application went viral. Five days after its release, it had garnered 1 million...
STAT+: 6 things to know about Apellis' eye drug ahead of FDA decision
The Food and Drug Administration is nearing a decision on the first treatment for geographic atrophy, a progressive eye disease and a leading cause of blindness in older...
Opinion: Unlocking the promise of learning from everyone with cancer
Locked behind the firewalls of proprietary systems sits a treasure trove of data that could help diagnose heart disease, diabetes, cancer, and other conditions faster and more...